LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.01730-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Wen Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lysigen, a Precisio Biotix Therapeutics company, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lysins are peptidoglycan hydrolases with great promise as novel and highly differentiated biotherapeutic agents. Here, we characterize LYSG101, a chimeric lysin active against all Staphylococcus species, including Staphylococcus aureus . LYSG101 exhibits potent activity against a range of clinical isolates, including methicillin-resistant S. aureus (MRSA) and coagulase-negative staphylococci (CoNS). Minimum inhibitory concentrations that inhibited 50% (MIC 50 ) and 90% (MIC 90 ) of S. aureus strains tested were 1 and 2 µg/mL, respectively, in cation-adjusted Mueller-Hinton broth (CAMHB) and 0.0625 and 0.125 µg/mL, respectively, in CAMHB + 25% horse serum, with no resistant outliers. LYSG101 is bactericidal, based on minimum bactericidal concentration (MBC) values within one log 2 dilution of MIC values, and >3-log 10 reduction within 15 min of exposure to lysin in time-kill assays. Serial passage resistance assays demonstrated no development of resistance to LYSG101 following 100 daily passages, whereas mupirocin resistance increased up to 500-fold over the same period. LYSG101 effectively disrupted S. aureus and CoNS biofilms. In vivo , LYSG101 significantly improved survival in murine models of intraperitoneal and intravenous S. aureus infection at 0.25 mg/kg ( P < 0.01 for both), and resulted in a significant reduction in lung CFU ( P < 0.0001) in a neutropenic lung infection model. These findings support the potential of LYSG101 as a new and effective therapeutic agent for staphylococcal infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lysigen, a Precisio Biotix Therapeutics company, Wuhan, Hubei, China.
ORCID-Profile: Assaf Raz
Zitieren
APA
Xiao, W., Fang, T., Guan, J., Ren, J., Thandar, M., Jin, G., Wang, M., Gan, N., Ma, F., & Raz, A. (2026). LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01730-25
Vancouver
Xiao W, Fang T, Guan J, Ren J, Thandar M, Jin G, et al. LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01730-25
BibTeX
@article{Xiao2026,
author = {Xiao, Wen and Fang, Tian and Guan, Jiawen and Ren, Jie and Thandar, Mya and Jin, Guanghuai and Wang, Menglin and Gan, Ning and Ma, Fuye and Raz, Assaf},
title = {LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.01730-25}
}
EUVIMED